Skip to content

US · WHWK · BIOTECHNOLOGY

Whitehawk Therapeutics Inc (WHWK) intrinsic value and stock valuation

$3.07as of 2026-11-21 · Mkt cap 235.39M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Whitehawk Therapeutics Inc DCF and intrinsic value

InvestorsCraft values WHWK with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from WHWK’s statements →

Whitehawk Therapeutics Inc Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Morristown, NJ 07960 ir.whitehawktx.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$7.14M-13.3% 5y CAGRd
20192025
Net income
-$-20.6M
20192025
Free cash flow
-$-97.98M
20192025
Total equity
$136.3M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$7.14M$26M$24.4M$15.2M$1.12M
Operating income-$-114.4M-$-67.46M-$-71.93M-$-62.68M-$-111.22M
Net income-$-20.6M-$-63.69M-$-65.77M-$-60.51M-$-110.09M
EPSd-$-332.85K-$-2.36M-$-2.44M-$-2.69M-$-12.34M
Operating cash flow-$-97.43M-$-59.55M-$-59.66M-$-49.64M-$-22.42M
Capital expenditure-$-550K-$-1.65M-$-3.97M-$-440K-$-50K
Free cash flow-$-97.98M-$-61.2M-$-63.63M-$-50.08M-$-22.47M
Total assets$150.8M$70.3M$132.4M$184.2M$157.9M
Total debt$0.00$830K$1.27M$1.66M$600K
Net debt-$-37.57M-$-27.84M-$-61.62M-$-37.36M-$-148.38M
Total equity$136.3M$52.5M$105.2M$158.4M$136.4M
Cash and short-term investments$145.7M$47.2M$108.8M$172.6M$149M
Income statement
20252024202320222021
Revenue$7.14M$26M$24.4M$15.2M$1.12M
Cost of revenue$760K$54.1M$51.7M$34M$19.7M
Gross profit$6.38M-$-28.07M-$-27.38M-$-18.78M-$-18.55M
Research and development expenses$91M$51M$48.9M$32.7M$19.7M
Selling, general and administrative expenses$29.8M$36.8M$44.6M$40.2M$18.5M
Other expenses$0.00-$-48.39M-$-48.93M-$-28.94M$54.5M
Operating expenses$120.8M$39.4M$44.6M$43.9M$92.7M
Cost and expenses$121.6M$93.4M$96.3M$77.9M$112.3M
Interest income$6.23M$3.92M$6.4M$2.4M$10K
Interest expense$0.00$150K$230K$230K$670K
Depreciation and amortization$80K$190K$170K$160K$100K
Ebitda-$-20.52M-$-64.63M-$-65.36M-$-58.8M-$-36.96M
Operating income-$-114.4M-$-67.46M-$-71.93M-$-62.68M-$-111.22M
Total other income/expenses, net$93.8M$3.77M$6.17M$2.17M$1.13M
Income before tax-$-20.6M-$-63.69M-$-65.77M-$-60.51M-$-110.09M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-20.6M-$-63.69M-$-65.77M-$-60.51M-$-110.09M
Weighted average shares outstanding$61.9M$27M$26.9M$22.5M$8.87M
Weighted average diluted shares outstanding$61.9M$27M$26.9M$22.5M$8.92M
Balance sheet
20252024202320222021
Cash and short-term investments$145.7M$47.2M$108.8M$172.6M$149M
Net receivables$0.00$5.9M$5.49M$1.86M$0.00
Inventory$0.00$5.31M$6.43M$1.86M$0.00
Total current assets$149M$61.3M$124.6M$180M$151.3M
Property, plant and equipment, net$0.00$7.63M$5.97M$2.03M$610K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$3.81M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$1.82M$9.03M$7.84M$4.21M$6.64M
Total assets$150.8M$70.3M$132.4M$184.2M$157.9M
Accounts payable$920K$2.16M$5.9M$3.52M$6.44M
Short-term debt$0.00$270K$430K$390K$130K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$14.5M$17.1M$26.4M$18.8M$15.3M
Long-term debt$0.00$560K$830K$1.27M$470K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$770K$830K$7.02M$6.23M
Capital lease obligations$0.00$830K$1.27M$1.66M$600K
Total liabilities$14.5M$17.8M$27.2M$25.9M$21.5M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-353.25M-$-332.65M-$-268.96M-$-203.2M-$-142.69M
Accumulated other comprehensive income (loss)$120K$20K$30K-$-120K$0.00
Total equity$136.3M$52.5M$105.2M$158.4M$136.4M
Total investments$108.1M$18.6M$46M$133.5M$0.00
Total debt$0.00$830K$1.27M$1.66M$600K
Net debt-$-37.57M-$-27.84M-$-61.62M-$-37.36M-$-148.38M
Cash flow statement
20252024202320222021
Net income-$-20.6M-$-63.69M-$-65.77M-$-60.51M-$-110.09M
Depreciation and amortization$80K$190K$170K$160K$100K
Stock-based compensation$9.87M$10.8M$12M$9.64M$2.11M
Change in working capital$1.93M$3.72M-$-3.27M-$-5.04M$3.96M
Accounts receivable-$-1M-$-410K-$-3.63M-$-1.86M$14.2M
Inventory$170K$1.12M-$-3.27M-$-1.86M$0.00
Accounts payable$3.92M$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-97.43M-$-59.55M-$-59.66M-$-49.64M-$-22.42M
Investments in property, plant and equipment-$-550K-$-1.65M-$-3.97M-$-440K-$-50K
Acquisitions, net$101.3M$0.00$0.00$0.00$25.2M
Net cash used for investing activities$11.9M$25.2M$83.2M-$-132.89M$25.2M
Common stock issued$100M$130K$0.00$72.5M$155M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00-$-4.41M
Net cash used for financing activities$94.4M$130K$330K$72.6M$141.8M
Net change in cash$8.9M-$-34.22M$23.9M-$-109.91M$144.5M
Cash at end of period$37.6M$28.7M$63M$39.1M$149M
Operating cash flow-$-97.43M-$-59.55M-$-59.66M-$-49.64M-$-22.42M
Capital expenditure-$-550K-$-1.65M-$-3.97M-$-440K-$-50K
Free cash flow-$-97.98M-$-61.2M-$-63.63M-$-50.08M-$-22.47M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Whitehawk Therapeutics Inc

        Whitehawk Therapeutics Inc. is a biopharmaceutical enterprise currently undergoing clinical trials. This company specializes in crafting highly targeted treatment options for cancers that are identified by distinct genetic profiles.

        CEO
        David J. Lennon
        Employees
        29
        Beta
        0.77

        Explore

        Frequently asked questions

        What is the intrinsic value of Whitehawk Therapeutics Inc (WHWK)?

        Whitehawk Therapeutics Inc (WHWK) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is WHWK undervalued?

        WHWK trades at a price of $3.07 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.